Dennis Slamon

Dennis Joseph Slamon (born August 6, 1948), is an American oncologist and chief of the division of Hematology-Oncology at UCLA. He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.

He currently serves as director of Clinical/Translational Research at UCLA's Jonsson Comprehensive Cancer Center, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a fund-raising organization that promotes advances in colorectal cancer. Provided by Wikipedia
Showing 1 - 1 results of 1 for search 'Dennis Slamon', query time: 0.02s Refine Results
  1. 1
    Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis

    Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis by Sandra M. Swain, Harrison Macharia, Javier Cortes, Chau Dang, Luca Gianni, Sara A. Hurvitz, Christian Jackisch, Andreas Schneeweiss, Dennis Slamon, Pinuccia Valagussa, Yolande du Toit, Dominik Heinzmann, Adam Knott, Chunyan Song, Patricia Cortazar

    Published 2022-10-01
    Get full text
    Article

Search Tools: